CN113694191A - 螺杆菌治疗剂 - Google Patents

螺杆菌治疗剂 Download PDF

Info

Publication number
CN113694191A
CN113694191A CN202110962088.5A CN202110962088A CN113694191A CN 113694191 A CN113694191 A CN 113694191A CN 202110962088 A CN202110962088 A CN 202110962088A CN 113694191 A CN113694191 A CN 113694191A
Authority
CN
China
Prior art keywords
htra
fragment
polypeptide
amino acids
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202110962088.5A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·萨顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Murdoch Childrens Research Institute
Original Assignee
Murdoch Childrens Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014902493A external-priority patent/AU2014902493A0/en
Application filed by Murdoch Childrens Research Institute filed Critical Murdoch Childrens Research Institute
Publication of CN113694191A publication Critical patent/CN113694191A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202110962088.5A 2014-06-30 2015-06-30 螺杆菌治疗剂 Pending CN113694191A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014902493A AU2014902493A0 (en) 2014-06-30 Helicobacter therapeutic
AU2014902493 2014-06-30
CN201580035276.6A CN106573038A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580035276.6A Division CN106573038A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Publications (1)

Publication Number Publication Date
CN113694191A true CN113694191A (zh) 2021-11-26

Family

ID=55018143

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202110962088.5A Pending CN113694191A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂
CN201580035276.6A Pending CN106573038A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580035276.6A Pending CN106573038A (zh) 2014-06-30 2015-06-30 螺杆菌治疗剂

Country Status (9)

Country Link
US (3) US20170165347A1 (enExample)
EP (1) EP3160492A4 (enExample)
JP (1) JP6634444B2 (enExample)
KR (1) KR102481455B1 (enExample)
CN (2) CN113694191A (enExample)
AU (1) AU2015283805B2 (enExample)
BR (1) BR112016030728A2 (enExample)
RU (1) RU2017100658A (enExample)
WO (1) WO2016000022A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101885460B1 (ko) 2017-02-07 2018-08-03 두산중공업 주식회사 가스터빈용 프리 스월러 장치
CN108531468B (zh) * 2018-02-24 2020-07-17 广东工业大学 编码重组幽门螺杆菌丝氨酸蛋白酶的基因、卵黄抗体与应用
KR102500799B1 (ko) 2018-03-09 2023-02-20 삼성디스플레이 주식회사 트랜지스터 기판 및 이를 구비하는 표시 장치
RU2746590C1 (ru) * 2020-10-12 2021-04-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Вятский государственный университет" Способ эрадикации бактерий Helicobacter pylori при экспериментальном хеликобактериозе у конвенциональных белых мышей и средство для его осуществления

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
EP1170368B1 (en) 1994-01-27 2010-07-28 University Of Massachusetts Medical Center Immunization by inoculation of dna transcription unit
US5939400A (en) 1996-02-26 1999-08-17 The Board Of Trustees Of The Leland Stanford Junior University DNA vaccination for induction of suppressive T cell response
US6110898A (en) 1996-05-24 2000-08-29 University Of Maryland, Baltimore DNA vaccines for eliciting a mucosal immune response
EP0977864A2 (en) * 1997-04-25 2000-02-09 Genelabs Technologies, Inc. Antigenic composition and method of detection for helicobacter pylori
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
GB9808720D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
US6585975B1 (en) * 1998-04-30 2003-07-01 Acambis, Inc. Use of Salmonella vectors for vaccination against helicobacter infection
AUPP684998A0 (en) * 1998-10-30 1998-11-26 Murdoch Institute for Research into Birth Defects Limited, The A method of recombination and agents useful for same
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
AU2001258373A1 (en) * 2000-04-27 2001-11-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying helicobacter antigens
US7015033B1 (en) * 2000-05-25 2006-03-21 Aventis Pasteur Limited Co-expression of recombination proteins
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
FR2815544B1 (fr) 2000-10-23 2003-02-14 Poudres & Explosifs Ste Nale Seringue sans aiguille securisee a architecture compacte
AT410798B (de) * 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
EP1622933A2 (en) * 2003-04-22 2006-02-08 Intercell AG H. pylori antigens
WO2007087576A2 (en) * 2006-01-24 2007-08-02 The Uab Research Foundation Compositions and methods for the identification and treatment of immune-mediated inflammatory diseases
EP2004678A1 (en) * 2006-03-15 2008-12-24 Csir Modulation of glutamine synthetase activity
WO2009026615A1 (en) * 2007-08-24 2009-03-05 University Of Wollongong Group a streptococcus pharmaceutical compositions and methods thereof
WO2010068413A1 (en) * 2008-11-25 2010-06-17 Emergent Product Development Gaithersburg Inc. Chlamydia vaccine comprising htra polypeptides

Also Published As

Publication number Publication date
RU2017100658A3 (enExample) 2019-02-19
KR20170016989A (ko) 2017-02-14
JP2017521490A (ja) 2017-08-03
CN106573038A (zh) 2017-04-19
AU2015283805A1 (en) 2017-01-05
US11819546B2 (en) 2023-11-21
US20220193216A1 (en) 2022-06-23
JP6634444B2 (ja) 2020-01-22
US20200108135A1 (en) 2020-04-09
EP3160492A4 (en) 2018-01-03
BR112016030728A2 (pt) 2018-02-20
AU2015283805B2 (en) 2021-02-25
WO2016000022A1 (en) 2016-01-07
EP3160492A1 (en) 2017-05-03
KR102481455B1 (ko) 2022-12-26
RU2017100658A (ru) 2018-07-30
US20170165347A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
US11819546B2 (en) Helicobacter therapeutic
CN107073095B (zh) 基于脂多糖缺失的细胞组分的抗鲍氏不动杆菌疫苗
US7914802B2 (en) Mucosal vaccine adjuvants containing bacterial flagellins as an active component
EP3312192B1 (en) Immunogenic compositions containing bacterial outer membrane vesicles
RU2747296C2 (ru) Вакцинация с использованием альфа3 домена mica/b для лечения рака
CN106794236B (zh) A群链球菌疫苗
KR20240099291A (ko) 지질다당류 (lps) 결핍성 아시네토박터 바우마니이 다가 백신
US20120251577A1 (en) Selectively disrupted whole-cell vaccine
Liu et al. Nongenetically modified Lactococcus lactis‐adjuvanted vaccination enhanced innate immunity against Helicobacter pylori
CA2805361A1 (en) Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
KR20010088302A (ko) 헬리코박터 감염에 대한 비경구 면역화 방법에 있어서의ｌｔ 및 ｃｔ
KR102040665B1 (ko) 약독화된 폐렴구균 균주를 포함하는 약제학적 조성물 및 이의 용도
CN115151559A (zh) 葡萄球菌肽和使用方法
JP7410018B2 (ja) Ａ群レンサ球菌に対する免疫原性ペプチド
KR20210010882A (ko) 연쇄구균 독성 쇼크 증후군
JP2003507433A (ja) 敗血症治療において治療に用いる対象としての外膜タンパク質ａ、ペプチドグリカン関連リポタンパク質およびムレインリポタンパク質
RU2775621C2 (ru) Иммуногенный пептид против стрептококков группы а
Ozberk Design and evaluation of novel liposome-based peptide vaccines for improved efficacy against group A streptococcal infections of the mucosa and skin
WO2007068902A2 (en) Vaccine
Chakraborti Therapeutic Antibody Against Neisseria gonorrhoeae Lipooligosaccharide, a Phase-variable Virulence Factor
HK1238144B (zh) A群链球菌疫苗
WO2009144240A1 (en) Composition and method for the assay and treatment of anthrax

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination